Skip to main content

ORIGINAL RESEARCH article

Front. Oncol., 03 April 2019
Sec. Pharmacology of Anti-Cancer Drugs
This article is part of the Research Topic Design and Application of Innovative Local Treatments in Glioblastoma and Other Cancers View all 12 articles

RETRACTED: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

Updated
\r\nHanbo CaoHanbo Cao1Wenjun LiWenjun Li1Yizhou ZhouYizhou Zhou1Renxiang TanRenxiang Tan2Yue YangYue Yang1You ZhouYou Zhou1Qinglong Guo*Qinglong Guo1*Li Zhao*Li Zhao1*
  • 1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China
  • 2State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine, Nanjing, China

Citation: Cao H, Li W, Zhou Y, Tan R, Yang Y, Zhou Y, Guo Q and Zhao L (2019) Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway. Front. Oncol. 9:188. doi: 10.3389/fonc.2019.00188

Received: 19 January 2019; Accepted: 05 March 2019;
Published: 03 April 2019; Retracted: 20 April 2020.

Edited by:

Carmen Alvarez-Lorenzo, University of Santiago de Compostela, Spain

Reviewed by:

Agnieszka Zdzisława Robaszkiewicz, University of Łódź, Poland
Amarjit Luniwal, North American Science Associates Inc., United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.